Published on September 14, 2017 by

Canine rabies and human health

Recent years have seen increasing recognition of the importance of canine rabies to human health: the scientific community has increasingly embraced dog rabies as an interesting and important field of study, and the public-health community has ramped up control efforts, leading to striking control successes, particularly in the Americas. This article discusses a series of papers published from 2007 based on ground-breaking work on tracing canine rabies in Tanzania, as well as analyses of data from other parts of the world.

Published on September 14, 2017 by

The Hayflick Limit and Maladaptive T cell Aging

Human cells have a finite lifespan (Hayflick limit). The existence of this Hayflick limit with regards to immune cells known as T cells, implies that infections have a long-term immunological cost (IC) to the individual because they drive immune cells towards the end of their lifespan, eventually making most of those cells unavailable to respond to other infections. The development of an accurate IC measure will lead to a better predictor of the age of the adaptive immune system than chronological age.

Published on September 14, 2017 by

Moving Towards a reliable HIV Incidence test: How far have we come and how far do we have to go?

: In 1998, the US CDC announced the publication of a simple laboratory technique that would allow the differentiation of ‘recent’ from ‘longstanding’ HIV infections. Detection of recent infections with a laboratory test allows one to estimate HIV incidence using a cross-sectional survey. We believed the quest to be able to measure HIV incidence and monitor the epidemic in real time was over. How wrong we were! Eighteen years later we published a paper highlighting the incredible progress that has been made, but also outlined the many difficulties that remain.

Short item Published on September 14, 2017

Progress in HIV science illuminated at the IAS2017 conference

The biennial International AIDS Society (IAS) Conference on HIV Science was held in Paris, France in July 2017. This article presents some of the highlights of the conference, including the roll of PrEP and the promise of long-acting injectable ARVs, as well as contributions of SACEMA staff in the areas of HIV and Hepatitis C, and HIV and cervical cancer. Basic, clinical, epidemiological and operational research on HIV and the HIV response must continue to be prioritised even while we strengthen our health systems and improve the implementation of existing interventions.

Short item Published on September 14, 2017

SACEMA Research Days 2017

SACEMA’s 11th annual ‘Research Days’ meeting took place over four days 21 – 24 August 2017, in Stellenbosch. All SACEMA funded students and their supervisors were invited, together with some associates and collaborators. The meeting included training workshops, keynote talks, formal research presentations, student and supervisor forums, and a debate.

Published on June 15, 2017 by

The role of cities in ending the AIDS epidemic

City leaders across the world are showing commitment and are providing political and technical leadership in dealing with local issues and barriers to delivering health and social services where they are needed. Cities are taking action, through their networks and by involving affected communities, to achieving the HIV Fast-Track targets by 2020. Ending the AIDS epidemic in cities will have profound, long-lasting benefits for urban communities and for countries and the global community.

Published on June 15, 2017 by

HIV infection and tuberculosis mortality among adults in Cape Town

Although a curable disease, tuberculosis (TB) remains a significant cause of mortality worldwide. To create a basis for further research into TB and HIV-associated mortality in Cape Town, we conducted a retrospective analysis of deaths occurring during TB treatment. A binomial log-linear regression model was used to investigate risk factors associated with death during TB treatment. We specifically looked at interactions between HIV infection and various other risk factors towards the risk of death from TB during treatment.

Newer Posts
Older Posts